

Please type a plus sign (+) inside this box ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-00311

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/554,531
				Filing Date	August 8, 2000
				First Named Inventor	Beeley
				Group Art Unit	1614
				Examiner Name	
Sheet	/	of	3	Attorney Docket Number	030639.0054 UTL (238/087 US)

U.S. PATENT DOCUMENTS						
Examiner Initials	Cite No <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MMDDYYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Cod& (if known)			
<i>cm</i>		5,424,286		Eng	06131995	

FOREIGN PATENT DOCUMENTS							
Examiner Initials	Cite No <sup>1</sup>	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MMDDYYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office	Number				
<i>cm</i>		AU	723694	Roche Diagnostics	01051998		

Examiner Signature	<i>cm</i>	Date Considered	2-20-01
-----------------------	-----------	--------------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents, <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete, Time will vary depending upon the needs of the individual case. Any comments on amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-00311

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	09/554,531
				Filing Date	August 8, 2000
				First Named Inventor	Beeley
				Group Art Unit	1614
				Examiner Name	
Sheet	2	of	3	Attorney Docket Number	030639.0054 UTL (238/087 US)

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
Cmm		D'ALESSIO, et al., "Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons," <u>J. Clin. Invest.</u> 97:133-138 (1996)		
		DANIEL, et al., "Use of Glucagon in the Treatment of Acute Diverticulitis," <u>Br. Med. J.</u> , 3:720 (1974)		
		EISSELE, et al., "Rat gastric somatostatin and gastrin release: Interactions of exendin-4 and truncated glucagon-like peptide-1 (GLP-1) amide," <u>Life Sci.</u> 55:629-634 (1994)		
		ENG, et al., "Isolation and characterization of exendin-4, an exendin-3 analogue, from heloderma suspectum venom," <u>J. Biol. Chem.</u> 267:7402-7405 (1992)		
		ENG, et al., "Purification and structure of exendin-3, a new pancreatic secretagogue isolated from heloderma horridum venom," <u>J. Biol. Chem.</u> 265:20259-20262 (1990)		
		GLAUSER, et al., "Intravenous Glucagon in the Management of Esophageal Food Obstruction," <u>J. Am. Coll. Emergency Physns.</u> , 8:228 (1979)		
		GOKE, et al., "Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)- amide receptor of insulin-secreting $\beta$ -cells," <u>J. Biol. Chem.</u> 268:19650-19655 (1993)		
		MALHOTRA, et al., "Exendin-4, a new peptide from Heloderma suspectum venom, potentiates cholecystokinin-induced amylase release from rat pancreatic acini," <u>Regulatory Peptides</u> 41:149-156 (1992)		
		O'HALLORAN, et al., "Glucagon-like peptide-1 (7-36)-NH <sub>2</sub> : A physiological inhibitor of gastric acid secretion in man," <u>J. Endocrinol.</u> 126(1):169-173 (1990)		
		ORSKOV, et al., "Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable," <u>Diabetes</u> 42:658-661 (1993)		
		RAUFMAN, et al., "Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas," <u>J. Biol. Chem.</u> 267:21432-21437 (1992)		
	✓		SCARPIGNATO, et al, "Action of Caerulein on Gastric Emptying of the Conscious Rat," <u>Arch. int. Pharmacodyn.</u> 246:286-294 (1980)	
		SCHEPP, et al., "Exendin-4 and exendin-(9-39) NH <sub>2</sub> : Agonist and antagonist, respectively, at the rat parietal cell receptor for glucagon-like peptide-1-(7-36)NH <sub>2</sub> ," <u>Eur.</u>		
Examiner Signature	Cmm		Date Considered	2-20-04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents, <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete, Time will vary depending upon the needs of the individual case. Any comments on amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box ☐

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-00311

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	09/554,531		
		Filing Date	August 8, 2000		
		First Named Inventor	Beeley		
		Group Art Unit	1614		
		Examiner Name			
Sheet	3	of	3	Attorney Docket Number	030639.0054 UTL (238/087 US)

		J. Pharmacol. 269:183-191 (1994)	
Cm		SCHJOLDAGER, et al., "GLP-1 (Glucagon-like peptide 1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in humans," <u>Dig Dis. Sci.</u> 34(5):703-708 (1989)	
		SINGH, et al., "Use of 125I-[Y39] exendin-4 to characterize exendin receptors on dispersed pancreatic acini and gastric chief cells from guinea pig," <u>Regul. Pept.</u> 53:47-59 (1994)	
		STOWER, et al., "A Trial of Glucagon in the Treatment of Painful Biliary Tract Disease," <u>Br. J. Surg.</u> , 69:591-592 (1982)	
		THORENS, "Expression cloning of the pancreatic $\beta$ cell receptor for the gluco-incretin hormone glucagon-like peptide 1," <u>Proc. Natl. Acad. Sci. USA</u> 89:8641-8645 (1992)	
		WETTERGREN, et al, "Truncated GLP-1 (Proglucagon 78-107-Amide) Inhibits Gastric and Pancreatic Functions in Man," <u>Digestive Diseases and Sciences</u> , 38(4):665-673 (1993)	
		WILLMS, et al., "Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: Effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (Noninsulin-dependent) diabetic patients," <u>J. Clin. Endocrinol. Metab.</u> 81(1):327-332 (1996)	

Examiner Signature	Cm	Date Considered	2-20-04
--------------------	----	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents, 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)		<b>Application Number</b>	09/554,531
		<b>Filing Date</b>	August 8, 20
		<b>First Named Inventor</b>	Arnold Beeley
		<b>Group Art Unit</b>	1614
		<b>Examiner Name</b>	C. Delacroix Muirhe
		<b>Attorney Docket Number</b>	030639.0054.UTL

TECH CENTER 1600/2900

RECEIVED  
MAY 29 2002

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
CPM		WO	98/05351		Amylin Pharmaceuticals, Inc.	2/12/1998	
		WO	98/30231		Amylin Pharmaceuticals, Inc.	7/16/1998	
		WO	99/07404		Amylin Pharmaceuticals, Inc.	2/18/1999	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		

Examiner Signature	CPM	Date Considered	2-20-04
--------------------	-----	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation is not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.